



# Bridge **discovery** & **decision-making** with **actionable omics**.

With robust multi-omics services and our DynamiQ™ molecular-clinical database, Sapient **generates diverse molecular data, integrates it across every omics layer, and grounds it in real-world human evidence – de-risking your development.**

We are helping to decipher the heterogeneity in disease biology and patient response, integrating multiple layers of molecular data for:

## Deeper biology.

We go beyond the genome to profile functional biology via **dynamic protein, metabolite, lipid, and cytokine biomarkers – the ultimate effectors of health and disease states**. This bridges the gap between inferred biology and mechanistic understanding.

## Smarter decisions.


By **identifying actionable biological mechanisms**, we help you accelerate go/no-go decisions and confidently:

- Identify & validate targets
- Stratify patients
- Predict efficacy
- Monitor response

**Proteomics & Protein Assays**



**Metabolomics & Lipidomics**



**Cytokine Profiling**



**Multi-Omic Studies**



## Faster breakthroughs.

Through expert data interpretation, we deliver outputs made to *act on* – **layering omics data to orthogonally validate findings and extend discoveries** with reproducible, multi-modal evidence.



# Move beyond “one gene, one protein, one disease” frameworks.

Diseases are rarely driven by a single factor, but rather shaped by a complex interplay of genetic and environmental influences. Sapient has developed our next-generation workflows to capture this complexity, allowing us to **analyze individual molecular changes – such as altered proteins or metabolites – within a broader biological context.**

These approaches can identify robust biomarker signatures and entire pathways involved in disease and drug response, enabling **more precise and effective therapeutic targeting.**

## Proteomics & Protein Assays

Elucidate functional biology, targets, and the influence of protein variants

Our mass spectrometry-based methods combine label-free, DIA workflows with advanced protein extraction and enrichment techniques to maximize proteome coverage across diverse sample matrices.

We offer **both discovery proteomics and targeted, quantitative assays across >12,000 protein groups, including proteoforms and post-translational modifications (PTMs).**

## Metabolomics & Lipidomics

Uncover dynamic downstream effects and physiological states

With high throughput workflows built upon our proprietary rapid LC-MS (rLC-MS) systems, Sapient enables metabolite and lipid biomarker discovery at an entirely new speed and scale.

We capture **>15,000 small molecule biomarkers across diverse chemistries**, identifying both known and novel molecules of biological significance.

### Proteins Measured by Matrix

|               |         |
|---------------|---------|
| Tissue / Cell | 12,000+ |
| FFPE Tissue   | 10,000+ |
| Plasma        | 5,400+  |
| CSF           | 3,600+  |
| Saliva        | 6,000+  |
| Urine         | 4,000+  |

### Metabolites & Lipids Captured

**15,000+ assayed** per sample including **polar metabolites and polar and non-polar lipids**

**Up to 1,400 identified** using Sapient's library of **>13,000 reference standards**

**Putative identification** using database of **>6M MS2 spectra**

## Cytokine Profiling

Quantify immune signaling mediators

As an Alamar Certified Service Provider (CSP), Sapiient offers **NULISA™ panels and assays for highly quantitative measures of difficult-to-assay, low-abundance proteins** that represent important inflammatory and CNS disease markers.

Move from data to breakthroughs in weeks, not months.

We deliver data *and* decision-ready insights, leveraging AI-powered data analysis and our DynamiQ™ Insights Engine to **uncover novel biology and validate findings that differentiate and strengthen your programs.**


**DynamiQ™**  
INSIGHTS ENGINE

- **>67,000 pre-characterized plasma samples** linked with rich metabolomics, multi-omics, and clinical data
- **Diverse tumor samples** across grades and stages and **normal human tissues** for global differential analyses

## Multi-Omic Studies

Bridge inferred and actual biology

We can integrate omics datasets – including from genomics, RNAseq, single-cell sequencing, and spatial profiling – to **improve mechanistic understanding by linking upstream regulation to downstream functional outcomes.**



### DynamiQ Applications


#### Biological Contextualization & Preclinical Translation

We use this large-scale reference dataset to **confirm disease and clinical links** of biomarkers observed in your study and to **cross-validate** early findings in real-world cohorts.



#### Target Identification

Our tissue and tumor virtual biobank enables rapid discovery and validation of **tractable, disease-modifying targets** (proteins and PTMs).



#### Virtual Experiments

We offer rapid access to multi-omics data for **biomarker scouting and building foundation models** – without the hurdles of sample collection.



# What will our **actionable omics** deliver for you?

## More certainty through mechanistic context.

Directly interrogate functional biology that DNA and RNA can only infer – confirming disease and drug response mechanisms to **meaningfully de-risk translation**.

## More confidence with reproducible, multi-modal evidence.

Our proven methods deliver **high-precision, tightly QC'ed datasets at scale, across omics workflows** – which can be layered to validate hypotheses and extend discovery.

## Decision-ready insights that drive a differentiated advantage.

As the **only multi-omics partner with a population-scale molecular-clinical database**, we can both analyze your samples *and* validate the findings in independent real-world cohorts – grounding insights in human evidence as well as uncovering novel biology to differentiate your programs.

### Value Across Phases

#### Enhance **Discovery**

With **broad biomarker coverage** for:

- Target identification
- Pathway mapping
- Early disease detection
- Disease progression biomarkers

#### De-risk **Translation**

With **functional evidence** for:

- Target engagement validation
- Proof of mechanism
- Forward & reverse translation

#### Maximize **Clinical Success**

With **robust biomarkers** to optimize:

- Patient stratification
- Treatment response
- Dosing strategies
- Risk profiling



SAPIENT

Discover more today.

+ [sapient.bio](https://sapient.bio)

+ [discover@sapient.bio](mailto:discover@sapient.bio)

+ 858.290.7010